Condensed Consolidated Interim Statements of Comprehensive Loss (Unaudited) - USD ($)		3 Months Ended		6 Months Ended
		Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Income Statement [Abstract]
Revenues from sales of products		$ 16,546	$ 36,608	$ 60,377	$ 157,618
Cost of sales		(5,782)	(27,007)	(33,762)	(69,753)
Gross profit		10,764	9,601	26,615	87,865
Research and development expenses		(11,690)	(16,857)	(127,556)	(135,765)
Selling and marketing expenses		(57,031)	(88,775)	(114,279)	(157,921)
General and administrative expenses		(808,251)	(744,287)	(1,550,054)	(2,378,151)
Operating loss		(866,208)	(840,318)	(1,765,274)	(2,583,972)
Financing income (expenses), net		(81,055)	10,982	(76,119)	33,087
Other income, net (Note 5(1))		117,396	12,294	105,225	12,294
Changes in fair value of an investment in an associate measured under the fair value option (Note 3)		29,725	102,107	113,668	102,107
Net loss		(800,142)	(714,935)	(1,622,500)	(2,436,484)
Less: net loss attributable to non-controlling interests		12,694	5,430	65,488	13,301
Net loss attributable to the Company’s stockholders’ equity		$ (787,448)	$ (709,505)	$ (1,557,012)	$ (2,423,183)
Loss per share (basic)		$ (0.23)	$ (0.69)	$ (0.49)	$ (2.8)
Loss per share (diluted)		$ (0.23)	$ (0.69)	$ (0.49)	$ (2.8)
Basic weighted average number of shares of Common Stock outstanding	[1]	3,408,878	1,027,040	3,184,772	862,399
Diluted weighted average number of shares of Common Stock outstanding	[1]	3,408,878	1,027,040	3,184,772	862,399

[1] Adjusted to reflect one (1) for seven (7) reverse stock split in October 2023 (see note 1B).